Palvella Therapeutics (PVLA) Other Accumulated Expenses (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Other Accumulated Expenses data on file, last reported at $960000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 29.38% year-over-year to $960000.0 in Q1 2026; TTM through Mar 2026 was $960000.0, a 29.38% increase from a year earlier, with the FY2025 full-year figure at $705000.0, down 40.71% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $960000.0, up from $705000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for PVLA reached as high as $1.2 million in Q4 2024 and fell as low as $120000.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $711176.5 across 5 years, with a median of $637000.0 in 2022.
• Across the five-year window, Other Accumulated Expenses slumped 75.16% in 2023 and soared 890.83% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $483000.0 in 2022, then slumped by 75.16% to $120000.0 in 2023, then surged by 890.83% to $1.2 million in 2024, then slumped by 40.71% to $705000.0 in 2025, then soared by 36.17% to $960000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $960000.0 in Q1 2026, $705000.0 in Q4 2025, and $1.1 million in Q3 2025.